How much to invest in glycemic control of a patient with diabetes mellitus type 2? A constant dilemma for the Brazilian Public Health System (SUS)
Braz. J. Pharm. Sci. (Online)
;
55: e17197, 2019. tab, graf
Artículo
en Inglés
| LILACS
| ID: biblio-1019530
ABSTRACT
Diabetes mellitus type 2 (DM2) affects millions of people worldwide and causes several complications for the patient, consuming large sums of financial resources from the health services. This study aims to estimate the financial investment of DM2 treatment for glycemic control of the patient, from the point of view of the municipal Public Health System (SUS). The Delphi technique was used to validate the opinion of a team of judges, specialists in DM2, and health service managers, on the investment necessary for glycemic control of patients with DM2 through the application of questionnaires. In order for the patient to achieve glycated hemoglobin (A1c) < 7%, an investment of US$ 2,419.06 (value/patient/year) is necessary. As the value of A1c increases, investment is reduced. This result reveals the intention to allocate resources for the prevention of DM2 and its complications
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Costos de la Atención en Salud
/
Economía Farmacéutica
/
Diabetes Mellitus Tipo 2
Tipo de estudio:
Evaluación Económica en Salud
País/Región como asunto:
America del Sur
/
Brasil
Idioma:
Inglés
Revista:
Braz. J. Pharm. Sci. (Online)
Asunto de la revista:
Farmacologia
/
Teraputica
/
Toxicologia
Año:
2019
Tipo del documento:
Artículo
País de afiliación:
Brasil
Institución/País de afiliación:
Federal University of São João Del-Rei (UFSJ)/BR
/
University of São Paulo/BR
Similares
MEDLINE
...
LILACS
LIS